Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
1455-1470
Elena L
opez-Villar a, b Martos-Moreno a, c, d, Julie A. Chowen
, Gabriel A. a, c, d
, Shigeru Okada e, f
,
John J. Kopchick e, g, h, Jesus Argente a, c, d, *
a
Departments of Endocrinology and Pediatrics, Hospital Infantil Universitario Nin~o Jesus, Universidad Autonoma de Madrid,
Madrid, Spain
b
Oncohematology and Pediatrics, Hospital Infantil Universitario Nin~o Jesus, Madrid, Spain
c
Instituto de Investigacion La Princesa, Madrid, Spain
d
Centro de Investigacio n Biome dica en Red de Fisiopatologıa de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
Carlos III, Madrid, Spain
e
Edison Biotechnology Institute, Ohio University, Konneker Research Laboratories, Athens, OH, USA
f
Department of Pediatrics, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA
g
Molecular and Cellular Biology Program, Ohio University, Athens, OH, USA
h
Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA
Abstract
The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However,
the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceuti-
cal communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in
proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification
of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that
have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new
strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel
therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area.
Introduction
The incidence of diabetes mellitus type 2 (DM2) is increasing at an the obesity epidemic as DM2 is a comorbidity frequently seen in
alarming rate world-wide. This is due, in part, to the dramatic rise in obese patients [1]. Because not all obese patients develop DM2 and
doi: 10.1111/jcmm.12600
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
not all patients suffering from DM2 are obese or overweight [2], it is Sample preparation
of interest to understand the mechanisms underlying the association
between these two entities to predict which patients are at higher risk
for developing this disease, and possibly for the development of pre- The sample preparation of body fluids (blood, serum, urine and sali-
ventative therapies. DM2 appears as a result of insulin resistance. vary) or tissues (e.g. adipose) is an extremely important pre-requisite
During the ontogeny of this disease, the pancreas begins to produce for achieving robust and reproducible data via proteomics. Once the
greater amounts of insulin to maintain euglycemia that collectively body fluids and/or tissues have been obtained for future proteomic
overcomes this resistance. But as time advances, sufficient insulin analyses, they must be frozen rapidly (i.e. at 80°C in a bio-banking
levels cannot be maintained to control normal levels of glycemia. The system) usually in aliquots distributed in several vials to avoid sample
clinical characteristics of DM2 appear several years after the onset of deterioration from repeated freeze–thaw cycles. When working with
this process during which time the person is asymptomatic. Once adipose tissue samples, the selection of the representative areas from
DM2 clearly appears, it must be attended immediately as it is very dif- the human body is extremely important according to the clinical
ficult and practically impossible to reverse the disease progression. In research goal. Tissue handling is also of paramount importance as
any event, factors such as exercise and diet can ‘help’, as it is of different tissues will require different homogenization and processing
utmost importance to properly control DM2 through life style, and protocols. Several examples are explained in the following sections
early intervention of the factors previously mentioned may result in and in Table 1. For clinical proteomic purposes, changes can take
normal glucose levels. Thus, early detection, or even more impor- place in proteome assays that can easily modify experimental results.
tantly, the possibility of avoiding DM2 onset would be of extreme ben- For example, contamination of protein-samples can cause results to
efit. be skewed, as artefacts and/or contaminants can mask low expressed
The alteration of protein structure, function, production and inter- proteins during mass spectrometry (MS) analysis, and they can also
actions, in part if not completely, contributes to the underlying mech- give rise to poor protein-separation during electrophoresis and chro-
anism of many diseases including diabetes [3]. Comprehension of matography, and in addition, artefacts can interact with the given pro-
pathological-mechanisms whereby molecular and environmental tein, thus changing the 3D-structure [12].
actions lead to the development and progress of diabetes is important There are many steps that can be taken in protein handling and
for the prevention and treatment of this disease. In such an endeav- storage processes, which may help to minimize any damage and, in
our, approaches such as genomics, metabolomics and proteomics turn, maximize accuracy of results. Crucial steps in the process are to
are being applied to identify more specific biomarkers for DM2 for its use anti-proteases and anti-phosphatases, and to freeze the protein
early detection, management and for devising new therapies. In this sample quickly after harvesting in several vials. A very common pre-
review, we will focus on the use of proteomics for the identification of mise is that ‘there are no routine sample preparation-protocols’ for a
novel biomarkers, and perhaps, therapeutic targets for the identifica- given proteomic experiment; it is always necessary to optimize them
tion and subsequent treatment of DM2. As in any research study, effi- according to the clinical goals and according to the designed proteo-
cient and up-to-date methods must be established and used for mic strategies to be used. In any event, optimized protocols for a
selection and proper handling of the clinical samples and data [4]. given sample or samples from the same clinical assays can be used
Simply defined, proteomics is the large-scale study of proteins, routinely. Moreover, several international laboratories [from Human
particularly of their structures and functions [5, 6]. Proteins are vital Proteome Organization (HUPO), EUPA and SeProt] are standardizing
parts of living organisms, as they are the main components of all cel- specific protocols for storing clinical samples apart from those for
lular processes. The term proteomics was first coined in 1997 [7] as analysis via proteomics and MS using reproducible protocols from
an analogy with genomics, the study of an organism’s genome. The different laboratories. This is important when we carry out analyses
word proteome is a blend of protein and genome and was coined by and the data are coming from different experiments from different
Marc Wilkins in 1994 while working on the concept as a PhD student laboratories [13–15].
[8]. The proteome is the entire set of proteins [8] produced or modi- Although the amount of protein obtained from patient samples
fied by an organism or system. This will vary with time as a result of can be very low, clinical samples allow highly valuable data to be
distinct requirements or stresses that a cell or organism encounters. achieved even with a limited amount of samples. Once the type of
Proteomics allows the study of the entire set of proteins, produced or sample to be used has been selected, it is necessary to optimize the
modified by an organism or system and it varies with time and a vari- protocol for tissue disruption/cell-lysis or for the isolation of the pro-
ety of environmental factors. Indeed, it is formed on the basis of teins from body fluids using commercial reagents including protease
research and development of the Human Genome Project [9, 10]. and phosphatase inhibitors. When analysing serum/plasma, it may be
Thus, while the genome is static the proteome is dynamic. It is also a necessary to use an albumin/IgG depletion kit to identify proteins
fundamental component of functional genomics. While proteomics whose concentration is low [15].
generally refers to the large-scale experimental analysis of proteins in We have found that many proteins do not exist as a single form
a given cell/tissue/organism, techniques used in the studies can also but as isoforms probably generated by post-translational modifica-
be applied to protein identification and purification. One of the key tions (PTM) of a given protein. Thus, for any proteomic protocol
methodologies used in this area is mass spectrometry [11]. We will used, one must be knowledgeable about protein isoforms. In certain
discuss in detail the sample preparation step as a key issue for clinical instances, it is also recommended that the purified complex mixture
proteomic research in the following section. of proteins be dilapidated. Additionally, one often analyses a given tis-
2DE-DIGE MALDI-TOF Adipose tissue 9 higher expressed proteins in the adipocytes from old compared to young [92]
obese patients:
Prohibitin 1
Protein disulphide isomerase A3
Beta actin
Profilin
Aldo-ketoreductase 1 C2
Alpha crystallin B
Anexins A1, A5, A6
4 lower expressed proteins in the adipocytes from old compared to young
obese patients:
Keratin type 2 cytoskeletal 1
Keratin type 2 cytoskeletal 10
Haemoglobins A, B
Signal transducer and activator of transcription 3 as the central molecule in the
connectivity map and the apoptosis pathway
iTRAQ LC-MS/MS Heart tissue 29 proteins up-regulated from a total of 1.627, while 84 were down-regulated in [93]
the db/db mice compared with the control group
Calnexin was found to be decreased whereas integrin-linked protein kinase was
decreased in the phlorizin treated DM group compared with the DM group
SDS-PAGE LC-MS/MS/MS Subcellular fractionation of the mouse 3.287 identified proteins that form part of the adipocyte proteome [94, 95]
LTQ-FT ELISA preadipocyte cell line 3T3-L1 with and Useful information to unravel the complexity of the adipocyte in obesity
without insulin treatment into cytosol, Addressed that adiponectin is generally negatively associated with GH activity,
membrane, mitochondria and nuclear regardless of age
fractions and nuclear fractions Useful information about the associations of total and HMW adiponectin with
Genetically modified animal models insulin sensitivity and longevity
(bGH, GHA and GHR/ mice and Circulating adiponectin levels correlated strongly with inguinal fat mass, implying
tissue-samples the effects of GH on adiponectin are depot-specific
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Phosphoproteomics Brown adipocytes From the 40 insulin effectors identified, 7 (SDR, PKC binding protein, LRP-6 [96]
SILAC anti-pY and PISP/PDZK11, a potential calcium ATPases binding protein
immunoprecipitation
1457
J. Cell. Mol. Med. Vol 19, No 7, 2015
Table 1. Continued
1458
Tool Sample Resulting data Ref.
2DE-gels stained by Platelet-free plasma from the patients 53 differentially spot-proteins from which 51% were shown to be down-regulated [97]
Sypro-Ruby comparing Vit D deficiency
The HMW form of adiponectin is down-regulated in obese paediatric patients with
Vit D deficiency
Thrombospondin 1 (TSP1) is up-regulated while histone deacetylase 4 (HDAC4)
is down-regulated
SCX MS/MS Peripheral blood mononuclear cells TSP1 and HDAC4 recover their normal expression level due to physical exercises [98]
2DE-gels LC-MS/MS Liver sample A diet rich in n-3PUFA decreases the expression of regucalcin, aldehyde [99]
MALDI-TOF MS dehydrogenase
A diet rich in n-3 PUFA increases
the expression of a POLI protein-A-1, S-adenosylmethionine synthase, fructose
1,6 biphosphatase, ketohexokinase, malate dehydrogenase, GTP-specific succinyl
CoAsynthase, Ornithine aminotransferase, protein disulfide isomerase A3
2DE-gels MALDI-TOF Human subcutaneous (SQ) and white The levels of several proteins in human SQ-WAT are not homogeneous between [100]
MS and MS/MS adipose tissue (WAT) different WAT depots
Twenty-one proteins showed differential intensities among the six defined
anatomical locations, and 14 between the superficial and the deep layer (such as
vimentin, heat-shock proteins, superoxide-dismutase, fatty acid-binding protein,
alpha-enolase, ATP-synthase among others)
2DE-DIGE MALDI-TOF Visceral adipose tissue (VAT) from The presence of diabetes influences the VAT abundance of several proteins [83]
MS and MS/MS pre-obese diabetic patients Diabetic patients showed increased VAT abundance of glutathione
S-transferase Mu 2, peroxiredoxin-2, antithrombin-III, apolipoprotein A-IV, Ig j
chain C region, mitochondrial aldehyde dehydrogenase and actin, and
decreased abundance of annexin-A1, retinaldehyde dehydrogenase-1 and
vinculin, compared with their non-diabetic counterparts.
Label-free quantitative Salivary samples from patients This study demonstrates that differences exist between salivary proteomic profiles in [84]
proteomics with diabetes patients with diabetes based on the A1C levels
2DE MALDI-TOF MS Serum samples from obese children This research study establishes the bases of the utility of proteomics to assess [85]
and MS/MS clinical improvements in obesity.
Down-regulated proteins in obese patients: transthyretin apolipoprotein-A1,
apo-J/clusterin and vitamin D binding protein.
ApoA1 was further down-regulated under the presence of up-regulation insulin
resistance, whereas weight reduction induced its up-regulation.
Apolipoprotein-A1 and haptoglobin were validated via ELISA as true potential candidate biomarkers
Representative assays detailing in each column –the goals, technologies, type of sample to be analysed and the resulting data– are placed schematically in this table. 2DE-electrophoresis
is one the most common tools used in diabetes and obesity research studies when using proteomics. Nevertheless, currently, more scientific articles are appearing and showing the
advantages when applying HPLC or nano-HPLC coupled directly to mass spectrometry (LC-MS) to avoid losing low expressed proteins or putative biomarkers. Biomarkers, adipocyte
and insulin proteomes have been the most common goals followed by scientists to unravel diabetes and obesity pathologies. All of them –and many others– allowed us to advance and
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
ª 2015 The Authors.
establish the right platforms and current technology-innovations will permit improve diagnoses and refine therapies via identifying new biomarkers by proteomics.
J. Cell. Mol. Med. Vol 19, No 7, 2015
sue along with serum or urine. This type of complementary data may For example, if we have a particular interest in diabetes, fasting
or may not be easily interpreted but many clinical research studies samples should be collected and stored. Additionally, a patient’s
show that analysing both types of samples offers the possibility to phenotypic data must be recorded including age, sex, weight, BMI,
explain linked biological processes. Additionally, the selection of a fasting glucose and other clinically important parameters. These
given proteomic platform must be made according to the goal of the data should be obtained at diagnoses and at different states
experiment [16, 17]. For example, high-throughput–proteomic strate- throughout the disease. Protocols to store clinical samples should
gies may be useful for discovery of biomarkers specifically related to provide clear information on how and when the samples were col-
various stages of obesity and DM2, and they may help to improve lected, processed and organized to ensure their long-term integrity
current treatments and innovative therapies. On the other hand, once for the study of a given disease [21].
the target proteins are selected by the discovery phase of the
research, analysis of those proteins in the complex mixture of biologi-
cal samples can be conducted by selected reaction monitoring (SRM) Serum samples
or multiple reaction monitoring (MRM) assays. The sample-prepara-
tion of body fluids is a tedious but critical step in obtaining reliable One of the major difficulties in studying the serum proteome is
results [16–19]. For example, urine contains low levels of proteins that two major groups of serum proteins, albumin and immuno-
compared to blood and a large amount of sample and/or a concentra- globulins, comprise approximately 95% of the total, while the
tion procedure may be required for analyses. The timing of the sam- remaining 5% belongs to a variety of other protein types including
ple collection may influence the results because the protein cytokines, hormones, enzymes and cytoplasmic and nuclear pro-
composition of body fluids may be different according to the different teins. Those highly abundant proteins may generate substantial
stages of the treatment for each patient. Indeed, we hypothesize that background in any proteomic analysis and may mask the signifi-
the serum from a patient suffering DM2 may contain different protein cant changes in proteins of interest. Albumin and IgG can be
patterns at diagnoses (t0) during the treatment (t1) and also at the removed from serum using affinity chromatography to refine the
end of the therapy (t2). Nevertheless, there is no reference protein- identification of biomarkers (low expressed proteins) for a given
map for DM2 or for obesity; thus, if we are able to ‘build’ the protein- pathology [22]. However, since albumin interacts with many blood
pattern reference map of obesity and DM2 compared to healthy con- components, it is possible that by removing albumin, one may
trols, we should improve our understanding of these pathologies. inadvertently remove important proteins that are important to a
Clinical application of proteomics, applied according to space given pathology, in this case DM2.
(serum, urine, blood) and time (diagnoses, treatment and/or cured The lipids contained in serum can have an important role in spe-
states), can be used to study the evolution of patients suffering obes- cific pathologies, such as hyperlipidemia, cardiovascular diseases,
ity and DM2, to unravel the mechanisms involved in disease progres- etc., as they can interact with serum proteins. In some cases, it is
sion. In the end, we hope that the patients will benefit. necessary to remove these lipids to identify the required proteins.
In the following sections, we discuss specific details useful for Fractionating the serum via centrifugation allows one to then separate
carrying out obesity and DM2 proteomic research. chylomicrons, very low density lipoproteins (such as VLDLPs) from
the total protein sample [23–25].
Results of proteomic analyses comparing a diseased versus
Special issues concerning tissue/ healthy state and the different stages of the disease can ultimately
identify putative therapeutics and/or therapeutic targets as well as
blood sampling diagnostic biomarkers. It has been suggested that the concentration
of specific proteins in serum can be useful for the early detection of
As stated above, sample integrity and storage are key factors for insulin resistance and that this may even be possible before the
obtaining efficient and reproducible data. Within the last decade, the appearance of the symptoms [23, 24, 26]. Thus, identification of dif-
quantity and quality of stored samples are high because of the crea- ferentially expressed serum proteins could be potentially important
tion of biobanks including sample collection procedures. This implies for the prevention and treatment of DM2, even in obese children [26–
that the samples are kept intact, preserving their chemical and physi- 28].
cal characteristics that may ultimately result in data indicative of their
functions and/or roles within the cell. Thus, different types of samples
(blood, urine, tissues) from the patients with different pathologies are Proteomic methodologies
available for study [18, 19] or can be collected and properly stored in
an individual laboratory’s biobank. The most significant breakthrough in proteomics has been the use of
Another important step is related to the standardization of pro- MS for the identification of proteins directly obtained from clinical
tocols for data acquisition from different biobanks so that different samples or from samples in which the proteins were previously sepa-
disease states and/or changes throughout time can be compared rated by two dimensional (2DE) gel electrophoresis or chromatogra-
[20]. If one of the main goals is to establish a long-term repository phy. Typical MS based identification of a protein utilizes tryptic
of biological/clinical samples and to make these samples available digestion [29] prior to MS analysis to improve the accuracy or mass
to multiple scientific studies, then specific protocols must be used. measurements. Mass spectrometry ionizes protein or peptide sam-
During the last 10 years, TiO2 has emerged as the most common added to the culture media. The newly synthesized proteins within
of the metal oxide affinity chromatography based phosphopeptide cells have the same physical and chemical properties except for the
enrichment methods. This technique offers increased capacity com- mass differences as a result of the isotope [50].
pared to IMAC resins to bind and elute mono-phosphorylated pep-
tides. TiO2 exploits the same principle as IMAC, and is similarly prone
to non-specific retention of acidic non-phosphorylated peptides. How- Selected reaction monitoring or multiple reaction
ever, when loading peptides in 2,5-dihydroxybenzoic acid [39], gly- monitoring
colic and phthalic acids, non-specific binding to TiO2 is reduced,
thereby improving phosphopeptide enrichment without a chemical This is a quantitative proteomics MS/MS-based tool. When using ESI,
modification of the sample. TiO2 is often considered to be inter- first, a peptide precursor is selected and isolated to obtain an ion pop-
changeable with IMAC. It works on similar levels of sample quantity ulation that represents ‘the precursor’. Next, the ion population is
(e.g. micrograms of protein) for the identification of phosphorylation- fragmented to produce product ions or ‘daughter ions’. The signal-
sites by MS analysis. Recently, SIMAC [39–41] appeared as a phos- intensity of the fragmented ions represents the abundance of peptides
phopeptide enrichment tool that exploits the properties of IMAC cou- and/or proteins for a given sample. Indeed, this method allows for
pled to TiO2, making it possible to carry out more refined studies. absolute quantitative data. Selected reaction monitoring or MRM is
Another phosphopeptide enrichment procedure prior to MS analy- carried out in specific mass spectrometers called ‘tripe quadrupole’
sis is ZrO2 [42] and its principle is based on metal affinity chromatog- and ‘ion traps’. The sensitivity and specificity of such strategy is
raphy like IMAC and TiO2. ZrO2 permits the isolation of single extremely high. In SRM assays, two mass analyzers are used as static
phosphorylated peptides in a more selective manner than TiO2. It has, mass-filters to monitor a particular fragment-ion from a selected pre-
in fact, been successfully used in the large-scale characterization of cursor-ion. The resulting selectivity from the two filtering stages cou-
phosphoproteins [43–46]. Furthermore, strategies that consist of pled to the high-duty cycle data in quantitative assays allows for
fractionating and subsequently enriching phosphopeptides are based extremely high sensitivity [51–60] (Fig. 1 shows in a simple scheme
on strong cation/anion exchange (SCX and SAX) chromatography and of SRM/MRM useful for metabolic research.
HILIC interaction chromatography. Calcium phosphate precipitation is
also a useful pre-fractionation step to simplify and enrich phospho-
peptides from complex samples which can be coupled to IMAC [46].
Label-free quantification
Isobaric tag for relative and absolute This is a MS-based method that allows the determination of the rela-
tive amount of protein from 2 or more complex samples [61]. Label-
quantitation
free quantification does not use a stable isotope containing com-
pound to chemically bind to the proteins. In a label free quantitative
This technique allows the relative and absolute quantification of 2 to 8
proteomic analysis, protein mixtures are analysed directly and sam-
complex-samples at the same time [47]. It uses a multiplexed iso-
ples are compared to each other after independent analyses. As a
baric chemical tagging-reagent. This tag permits multiplexing of 2 to
result, there is no mixing of samples, so that higher proteome cover-
8 complex-protein samples and produces identical MS/MS sequenc-
age can be achieved and there is no limit to the number of experi-
ing ions for all 8 versions of the same derived tryptic peptide. Quanti-
ments that can be compared [62]. Moreover, label-free approaches
fication and analyses are performed via comparing the peak-areas
may be divided into two main groups by the way that the abundance
and peak-ratios in the MS/MS mode. The reporter-ions used are from
of a peptide is measured. The first group comprises methods that are
114 to 117 Da and from 113 to 119 and 121 Da. To carry out protein
based on the ion count and compare either maximum abundance or
expression level studies, it can be a good option to apply isobaric tag
volume of ion count for peptide peaks at specific retention times
for relative and absolute quantitation (iTRAQ), even though stable iso-
between different samples. Since ionized peptides elute from a
tope labelling by amino acids in cell culture (SILAC, when using cell
reversed-phase column into the mass spectrometer, their ion
lines) and/or MRM or SRM can also be successfully employed (see
intensities can be measured within the given detection limits of the
below) [48, 49].
experimental setup [43–45, 63–68] (Fig. 2 shows in a simple manner
SILAC is another approach for in vivo incorporation of a label into
the scheme of Label-free useful for metabolic research).
proteins for subsequent MS-quantitative analysis. The identification
step is currently carried out in MS/MS mode. Its principle is based on
metabolic incorporation of a given ‘light’ or ‘heavy’ form of the amino
acid into the proteins. Amino acids are incorporated via substituted Electrospray ionization and tandem mass
stable isotopic forms such as deuterium, 13C and 15N. Basically, dur- spectrometry MS-n (Nano-ESI-MSn)
ing SILAC experiments, two cell-populations are grown in a culture
media that is identical except that one contains the ‘light’ label and Tandem MS [69], ESI coupled with CID and MS/MS potentially repre-
the second one the ‘heavy’ label. These labels allow the comparison sents one of the most sensitive, discriminating and direct methods
of two physiological conditions (e.g. healthy versus ill). Two condi- for the qualitative and quantitative high-throughput analysis of sub-
tions are distinguished via the labelled analogue amino acid that was picomole amounts of protein. Nano-ESI-MS/MS allows identification
of the previously labelled and isolated proteins/peptides (and phos- intracellular signalling -networks are activated/deactivated via phos-
pho-proteins/peptides) coming from complex samples (i.e. blood phorylation during disease progression and (iii) determine which pro-
and/or CSF) and subsequently, data analyses of the quantified (from teins and phosphoproteins or other PTMs are up and/or down-
iTRAQ label) and modified residues (from isolation SIMAC) must be regulated in several clinical states (healthy or ill). The resulting data is
conducted via, for example, Matrix-Science Mascot searching (http:// specific for a given time and/or disease state (i.e. after diagnosis, dur-
www.matrixscience.com/cgi/search_form.pl?FORM- ing treatment) of a specific patient/s and according to each different
VER=2&SEARCH=MIS). type of sample (blood, sera, urine) as the proteome is dynamic (space
Through the previously mentioned tools, we can achieve: (i) iden- and time). Finally, the resulting identified protein-biomarkers can be
tification (ID) of protein candidate biomarkers, (ii) analyse how the validated by ELISA and/or western blotting and via SRM/MRM
assuming that an antibody is available for a given protein [70–72]. To applied to studies of DM2 and the identification of new biomarkers.
summarize, to obtain reliable and reproducible biomarker data, it is Figure 3 shows, in a simple manner, the basic work-flow useful for
always necessary to standardize protocols for the collection, han- metabolic research (Fig. 3). Below we briefly review some of the most
dling, storage and processing of samples for subsequent proteomic relevant studies in diabetes using proteomic approaches.
analyses using any of the procedures described above. These tools
allow the analysis of hundreds of proteins at a given time in a very
small sample size with high sensitivity. The main difference among Current and relevant studies of DM
these current techniques is related to the sensitivity, the detection-
level of the selected method [73–80].
and obesity using proteomic
approaches
Identification of proteins Yang et al. [82], carried out 2DE of peritoneal dialyzed samples. They
were able to visualize more than 300 protein-spots, from which 13
Mascot Server (http://www.matrixscience.com/) is commonly used protein spots were selected to be excised and the corresponding pro-
for identification, characterization and quantification of the resulting teins were digested and analysed by reverse-phase nano-ultra perfor-
proteins after MS results have been collected. It allows free searches mance LC-ESI-MS/MS. The resulting data confirmed 10 spots/
and contains protein sequence databases online from all organisms proteins with significant differential expression between the DM and
analysed to date. Through Mascot it is also possible to validate the chronic glomerulonephritis peritoneal dialyses samples. These
identified protein-biomarkers from the clinical proteomic research authors state that the differentially expressed proteins identified in
study via manual inspection of all the spectra. Manual validation of their study may not be new biomarkers. However, they also indicate
spectra is required by the best proteomic journals to ensure the high possible targets for drug treatment and protein profiles that could be
quality of data. New and efficient bioinformatic software is routinely predictors of peritonitis, indicating the necessity for validation studies
appearing on the market to carry out statistics and validation, espe- in the future. A possible way to validate the resulting identified pro-
cially for high-throughput analysis; thus, the validation-step can be tein-biomarkers from obesity and DM2 samples during clinical prote-
developed more efficiently. Interesting and useful bioinformatic tools omic research studies is via: (i) ELISA and/or western blotting (using
for proteomics research are well-established in other reviews [80, specific antibodies (Abs) for the identified potential biomarkers-) and
81]. (ii) via SRM/MRM [4]. Selected reaction monitoring or MRM is a
Thus, it is obvious that the methodology available to perform pro- method of MS/MS that allows one to monitor target peptides within a
teomics and phosphoproteomic studies has advanced dramatically in complex mixture of tryptic peptides. For example, proteins A1 and B2
recent years, to improve our understanding of intracellular signalling are discovered as biomarkers for DM2 at diagnosis in obese patients,
networks. These methodological advances are now beginning to be while proteins C3 and D4 are biomarkers for DM2 during treatment
cardiac lipid metabolism, mitochondrial function and cardiomyopathy. pY containing proteins/peptides-and quantify the level of their phos-
The resulting data suggests that phlorizin may prevent the develop- phorylation according to different stress and stimuli conditions over
ment of diabetic cardiomyopathy by regulating the expression of key insulin network [87].
proteins in these processes. They also showed that phlorizin signifi- Walker et al. [88] have recently suggested that in obesity the ‘net-
cantly decreases body weight-gain and circulating levels of glucose, works’ of metabolic signalling pathways are related to vitamin D
triglycerides, total cholesterol and glycosylated-end products. Their status and that vitamin D regulation of adiponectin involves post-
findings suggest that normal myocardial structure was better pre- translational-events. They coupled 2DE-gels plus MS to identify rele-
served after phlorizin treatment and that this drug can be a novel ther- vant molecules in obese children dichotomized according to 25OH
apeutic protocol for the treatment of diabetic cardiomyopathy, with vitamin D (25OHD) levels. Platelet–free plasma from 42 obese chil-
the proteomic data helping to identify the possible mechanism [85]. dren (M/F = 18/24) classified according to their 25OHD3 levels
Adipocytes play a central role in energy metabolism and in the (<15 ng/ml = deficient and >30 ng/ml = non-deficient) was analy-
obesity epidemic. Therefore, determining the protein composition of sed. Image analysis (ChemiDoc Imager and PD Quest –software to
adipocytes should help to unravel important biological questions. In analyse the resulting proteomic data-) was able to identify the pro-
such an endeavour, Mann et al. [86] studied the adipocyte-proteome tein-spots from 2DE-Sypro-gels that were differentially expressed
by proteomics plus mass spectrometry and bioinformatic tools. They according to each individual spot ‘volume’ via density/area integrating
first carried out subcellular fractionation of the mouse preadipocyte Sypro-Ruby staining to the Gaussian model. Their data showed 53
cell line 3T3-L1 with and without insulin treatment, into cytosol, differentially expressed protein-spots, from which 51% were down-
membrane, mitochondria and nuclear fractions. They used SDS-PAGE regulated (comparing VD deficiency and no deficiency of VD). One
gels from which the protein-bands were digested and the resulting interesting identified biomarker is the HMW form of adiponectin,
peptides were identified via LC-MS/MS/MS (LTQ-FT). They were able which was observed to be down-regulated in obese paediatric
to identify 3287 proteins that form part of the adipocyte proteome. patients with vitamin D deficiency. Additionally, the identified biomar-
Moreover, each fraction was analysed by western blotting and using kers are able to be modulated in vivo with vitamin D supplementation.
specific antibodies for each fraction. In addition, they validated all This proteomic approach represents a very interesting strategy to dif-
resulting data by bioinformatics, obtaining one of the largest high ferentiate phenotypes of diseases and also to study specific therapy
confidence proteomes reported. The adipocyte-proteome is available targets.
in the Max-Planck Unified Proteome database [86]. This article con- An important contributing factor for obesity and its associated
tains very useful information to unravel the complexity of the adipo- comorbidites is a sedentary lifestyle, in addition to excessive food
cyte in obesity and other pathologies [86]. intake. Abu-Farha et al. [89] recently published an interesting study
Another example from the group of Mann et al. [87] is related to applying high-through-put proteomic analyses of peripheral blood
unravelling the insulin induced intracellular signalling pathway via mononuclear cells (PBMCs). The PBMCs samples were purified from
phosphoproteomics. It is well-known that the insulin signalling path- lean and obese human males to identify and quantify differentially
way is very important in metabolic diseases and cellular processes of expressed proteins between both groups. In this study the mecha-
ageing. The insulin receptor and its substrates are fundamental in the nisms underlying obesity progression and the possibility of managing
insulin signalling-network, with insulin binding to its receptor to trig- this progression with physical exercises were analysed. Using SCX
ger tyrosine phosphorylation cascades that subsequently activate plus MS/MS, 47 proteins differentially expressed between lean and
other connected cascade networks. Understanding the activation of obese patients were identified [89]. Thrombospondin 1 (TSP1) was
connected signalling networks is the key to unravelling diverse bio- up-regulated while histone deacetylase 4 (HDAC4) was down-regu-
logical processes related to DM and obesity. To begin to understand lated and after 3 months of physical exercises, TSP1 and HDAC4
the network of the tyrosine phosphorylation cascade, Mann et al. returned to control levels.
identified the tyrosine-phosphoproteome of the insulin signalling Omega-3 polyunsaturated fatty acids (n-3 PUFA) are reported to
pathway by applying MS coupled to phosphotyrosine immunoprecipi- decrease the symptoms of diabetes, obesity and insulin resistance
tation and SILAC in differentiated brown adipocytes. They also quanti- related to the metabolic disorders. The proteins and pathways
fied the temporal dynamics of tyrosine phosphorylation events upon involved in the regulation of n-3 PUFA are unknown, especially those
insulin stimulation in differentiated brown adipocytes. The authors which produce beneficial health effects. Ahmed et al. [90] studied the
applied high resolution quantitative MS-based proteomic tools (SILAC effect of diets with high or low levels of n-3 PUFA on hepatic proteo-
and anti-pY immunoprecipitation) to identify and quantify 40 protein mic profile in mice. They applied 2DE-gels coupled to LC-MS/MS
effectors from the insulin pathway in differentiated brown adipocytes. analysis plus specific software (ImageScanner III; Progenesis Same-
To know the temporal dynamics of phosphorylation of proteins on spots, version 3.1). It is important to note that 800 lg of total protein
tyrosine, the authors applied a triple label of SILAC with three differ- needed to be loaded into 2DE-gels (it is now possible to use other
entially labelled cell populations being stimulated for different times. proteomic tools, mentioned above, to avoid the necessity of using
Data were corroborated by western blotting. From the 40 insulin ef- such a large amount of sample). The resulting protein-spots visual-
fectors identified, 7 (SDR, PKC binding protein, LRP-6 and PISP/ ized via 2DE were digested with trypsin and analysed by MALDI-TOF
PDZK11, a potential calcium ATPase binding protein) were described (MS). They also carried out analysis by tandem mass spectrometry
for the first time to be involved in insulin signalling. In addition, Mann via LC-MS/MS to identify protein-spots from the 2DE-gels. MALDI-
et al. indicate that this approach is capable of detecting the specific TOF MS is useful to study specific or a reduced number of protein-
knowledge of DM2 and obesity and identify new targets for diag- obesity (Fig. 4 summarizes the pros and cons (tips) of several prote-
nosis and treatment. omic methodologies useful for metabolic research). Thus, it will bene-
Liquid chromatography-mass spectrometry results in increased fit the patients and help to advance specific therapies. As a delegate
accuracy compared to 2DE-gels, especially because of the fact that of HUPO (http://www.hupo.org/; Fostering international proteomic ini-
LC-MS allows identification of low expressed proteins (good protein tiatives to better understand human disease), for human proteome on
candidate biomarkers). Thus, although important information has children assays and studies at Hospital Universitario Ni~no Jesus
been achieved via 2DE (especially concerning isoforms studies), new (Madrid, Spain), we are seeking to support the human proteome in
concepts can be reached when analysing clinical samples via proteo- this context. We envision this will further benefit the understanding of
mic approaches that directly apply LC-MS avoiding 2DE. the pathology of the diseases and ultimately improve the diagnoses
The new possibilities of proteomic strategies, which include SI- and personalized treatments in the near future; thus, patients will
MAC, iTRAQ, label-free and nano-ESI-LC-MSn, could result in the undoubtedly be benefited.
identification of new phosphorylated biomarkers in the intracellular
signalling networks involved in DM and obesity. It should be empha-
sized once more that correct clinical sample preparation is an essen-
tial pre-requisite and this should be standardized in biobanks.
Acknowledgements
To finalize, the advances in proteomic approaches and the com- This work is funded by Ministerio de Ciencia e Innovacion (BFU2011–27492),
plete sequence of the human proteome, will allow us to unravel Fondos de Investigacion Sanitaria (PI1302195), Centro de Investigacion
changes in the proteomic profile of clinical samples from obese Biomedica en Red Fisiopatologıa de Obesidad y Nutricion (CIBERobn), Instituto
patients with and without diabetes, as well as DM2 with and without de Salud Carlos III and Fundacion de Endocrinologıa y Nutricion. Dr. Elena
Fig. 4 Pros and cons of several proteomic tools useful in metabolic research. In this figure, a summary of pros and cons (tips) of several
proteomic methodologies, has been detailed, from sample preparation to get MS data. We aim to place useful tools for proteomic metabolic
research.
References
1. Martos-Moreno GA, Barrios V, Chowen JA, ing diabetes research. Expert Rev mice–an optimized rapid workflow for
et al. Adipokines in childhood obesity. Vi- Proteomics. 2014; 11: 491–502. SRM-based quantification. J Proteome
tam Horm. 2013; 91: 107–42. 15. Takahashi E, Okumura A, Unoki-Kubota Res. 2013; 12: 1331–43.
2. Soriano-Guillen L, Barrios V, Martos G, H, et al. Differential proteome analysis of 25. Chowen JA, Argente J, Horvath TL. Uncov-
et al. Effect of oral glucose administration serum proteins associated with the devel- ering novel roles of nonneuronal cells in
on ghrelin levels in obese children. Eur J opment of type 2 diabetes mellitus in the body weight homeostasis and obesity.
Endocrinol. 2004; 151: 119–21. KK-A(y) mouse model using the iTRAQ Endocrinology. 2013; 154: 3001–7.
3. Nagaraj NS, Singh OV, Merchant NB. Pro- technique. J Proteomics. 2013; 84: 40– 26. Okada S, List EO, Sankaran S, et al. Plasma
teomics: a strategy to understand the novel 51. protein biomarkers correlated with the devel-
targets in protein misfolding and cancer 16. Chen X, Andersson R, Cho WC, et al. The opment of diet-induced type 2 diabetes in
therapy. Expert Rev Proteomics. 2010; 7: international effort: building the bridge for mice. Clin Proteomics. 2010; 6: 6–17.
613–23. Translational Medicine: Report of the 1st 27. Granado M, Garcıa-Caceres C, Tuda M,
4. Lopez E, Madero L, Lopez-Pascual J, International Conference of Translational et al. Insulin and growth hormone-releas-
et al. Clinical proteomics and OMICS clues Medicine (ICTM). Clin Transl Med. 2012; 1: ing peptide-6 (GHRP-6) have differential
useful in translational medicine research. 15. beneficial effects on cell turnover in the
Proteome Sci. 2012; 10: 35. 17. Lopez E, Mu~noz SR, Pascual JL, et al. Rel- pituitary, hypothalamus and cerebellum of
5. Anderson NL, Anderson NG. Proteome and evant phosphoproteomic and mass spec- streptozotocin (STZ)-induced diabetic rats.
proteomics: new technologies, new con- trometry: approaches useful in clinical Mol Cell Endocrinol. 2011; 337: 101–13.
cepts, and new words. Electrophoresis. research. Clin Transl Med. 2012; 1: 2. 28. Iwadate Y. Clinical proteomics in cancer
1998; 19: 1853–61. 18. Prakash A, Tomazela DM, Frewen B, et al. research-promises and limitations of cur-
6. Blackstock WP, Weir MP. Proteomics: Expediting the development of targeted rent two-dimensional gel electrophoresis.
quantitative and physical mapping of cellular SRM Assays: using data from shotgun pro- Curr Med Chem. 2008; 15: 2393–400.
proteins. Trends Biotechnol. 1999; 17: 121–7. teomics to automate method development. 29. Olsen JV, Ong SE, Mann M. Trypsin
7. James P. Protein identification in the post- J Proteome Res. 2009; 8: 2733–9. cleaves exclusively C-terminal to arginine
genome era: the rapid rise of proteomics. Q 19. Gemoll T, L€owe O, Boren M, et al. The and lysine residues. Mol Cell Proteomics.
Rev Biophys. 1997; 30: 279–331. impact of pre-analytical conditions on the 2004; 3: 608–14.
8. Wilkins MR, Pasquali C, Appel RD, et al. serum proteome: heat-stabilization versus 30. Eng JK, McCormack AL, Yates JR. An
From proteins to proteomes: large scale nitrogen storage. Arch Physiol Biochem. approach to correlate tandem mass spec-
protein identification by two-dimensional 2013; 119: 100–7. tral data of peptides with amino acid
electrophoresis and amino acid analysis. 20. Malm J, Fehniger TE, Danmyr P, et al. sequences in a protein database. J Am Soc
Biotechnology. 1996; 14: 61–5. Developments in biobanking workflow stan- Mass Spectrom. 1994; 5: 976–89.
9. DeLisi C. Meetings that changed the world: dardization providing sample integrity and 31. Minden J. Comparative proteomics and dif-
Santa Fe 1986: human genome baby-steps. stability. J Proteomics. 2013; 95: 38–45. ference gel electrophoresis. Biotechniques
Nature. 2008; 455: 876–7. 21. Elliott P, Peakman TC. The UK Biobank 2007; 43: 739, 741, 743 passim.
10. DeLisi C. The Human Genome Project. Am sample handling and storage protocol for 32. Kopchick JJ, List EO, Kohn DT, et al. Per-
Sci. 1988; 76: 488–93. the collection, processing and archiving of spective: proteomics–see “spots” run.
11. Kussmann M, Morine MJ, Hager J, et al. human blood and urine. Int J Epidemiol. Endocrinology. 2002; 143: 1990–4.
Perspective: a systems approach to diabe- 2008; 37: 234–44. 33. Yang MH, Wang HY, Lu CY, et al. Proteo-
tes research. Front Genet. 2013; 4: 205. 22. Dhokia B, Pectasides D, Epenetos AA, mic profiling for peritoneal dialysate: differ-
eCollection 2013. et al. Serum levels of c-myc and c-ras ential protein expression in diabetes
12. Lopez E, Lopez I, Sequı J, et al. Discover- oncogene products in normal subjects and mellitus. Biomed Res Int. 2013; 2013:
ing and validating unknown phospho-sites in patients with neoplastic and non neo- 642964.
from p38 and HuR protein kinases in vitro plastic conditions. Int J Biol Markers. 1986; 34. Wu Q, Yuan H, Zhang L, et al. Recent
by Phosphoproteomic and Bioinformatic 1: 29–32. advances on multidimensional liquid chro-
tools. J Clin Bioinforma. 2011; 1: 16. 23. Bhonsle HS, Korwar AM, Chougale AD, matography-mass spectrometry for proteo-
13. Silva JL, Vieira TC, Gomes MP, et al. et al. Proteomic study reveals downregula- mics: from qualitative to quantitative
Ligand binding and in protein misfolding: tion of apolipoprotein A1 in plasma of analysis–a review. Anal Chim Acta. 2012;
insights from studies of prion and p53 poorly controlled diabetes: a pilot study. 731: 1–10.
tumor supresor proteins. Acc Chem Res. Mol Med Rep. 2013; 7: 495–8. 35. Crimmins DL. Applications of strong cat-
2010; 43: 271–9. 24. von Toerne C, Kahle M, Sch€afer A, et al. ion-exchange (SCX)-HPLC in synthetic pep-
14. Murri M, Insenser M, Luque M, et al. Pro- Apoe, Mbl2, and Psp plasma protein levels tide analysis. Methods Mol Biol. 1994; 36:
teomic analysis of adipose tissue: inform- correlate with diabetic phenotype in NZO 53–64.
36. Nakatani N, Kozaki D, Mori M, et al. 48. Evans C, Noirel J, Ow SY, et al. An insight tral counting in a proteomics screen. Prote-
Recent progress and applications of ion- into iTRAQ: where do we stand now? Anal omics. 2008; 8: 994–9.
exclusion/ion-exchange chromatography Bioanal Chem. 2012; 404: 1011–27. 64. Bridges SM, Magee GB, Wang N, et al.
for simultaneous determination of inor- 49. Ong SE. The expanding field of SILAC. Anal ProtQuant: a tool for the label-free quantifi-
ganic anions and cations. Anal Sci. 2012; Bioanal Chem. 2012; 404: 967–76. cation of MudPIT proteomics data. BMC
28: 845–52. 50. Holman SW, Sims PF, Eyers CE. The use Bioinformatics. 2007; 8: S24.
37. Thingholm TE, Jensen ON, Robinson PJ, of selected reaction monitoring in quantita- 65. Mueller LN, Brusniak MY, Mani DR, et al.
et al. SIMAC (sequential elution from tive proteomics. Bioanalysis. 2012; 4: An assessment of software solutions for
IMAC), a phosphoproteomics strategy for 1763–86. the analysis of mass spectrometry based
the rapid separation of monophosphory- 51. Law KP, Lim YP. Recent advances in mass quantitative proteomics data. J Proteome
lated from multiply phosphorylated spectrometry: data independent analysis Res. 2008; 7: 51–61.
peptides. Mol Cell Proteomics. 2008; 7: and hyper reaction monitoring. Expert Rev 66. Scholl PF. An intact protein LC/MS strat-
661–71. Proteomics. 2013; 10: 551–66. egy for serum biomarker development:
38. Lopez E, Wesselink JJ, Lopez I, et al. 52. de Hoffmann E. Tandem mass spectrome- Biomarkers of hepatic responsiveness to
Technical phosphoproteomic and bioinfor- try: a primer. J Mass Spectrom 1996; 31: chemopreventive treatment with the trit-
matic tools useful in cancer research. J Clin 129–37. erpenoid CDDO-Im, ASMS Conference,
Bioinforma. 2011; 1: 26. 53. Lange V, Picotti P, Domon B, et al. 2007.
39. Jensen SS, Larsen MR. Evaluation of the Selected reaction monitoring for quantita- 67. Schaab C, Geiger T, Stoehr G, et al. Analy-
impact of some experimental procedures tive proteomics: a tutorial. Mol Syst Biol. sis of high accuracy, quantitative proteo-
on different phosphopeptide enrichment 2008; 4: 222. mics data in the MaxQB database. Mol Cell
techniques. Rapid Commun Mass Spec- 54. Kondrat RW, McClusky GA, Cooks RG. Proteomics 2012; 11: M111.014068.
trom. 2007; 21: 3635–45. Multiple reaction monitoring in mass spec- 68. Van Riper SK, de Jong EP, Carlis JV, et al.
40. Larsen MR, Thingholm TE, Jensen ON, trometry/mass spectrometry for direct Mass spectrometry-based proteomics:
et al. Highly selective enrichment of phos- analysis of complex mixtures. Anal Chem. basic principles and emerging technologies
phorylated peptides from peptide mixtures 1978; 50: 2017–21. and directions. Adv Exp Med Biol. 2013;
using titanium dioxide microcolumns. Mol 55. Peterson AC, Russell JD, Bailey DJ, et al. 990: 1–35.
Cell Proteomics. 2005; 4: 873–86. Parallel reaction monitoring for high resolu- 69. Tao D, Zhang L, Shan Y, et al. Recent
41. Engholm-Keller K, Birck P, Størling J, tion and high mass accuracy quantitative, advances in micro-scale and nano-scale
et al. TiSH–a robust and sensitive global targeted proteomics. Mol Cell Proteomics. high-performance liquid-phase chromatog-
phosphoproteomics strategy employing a 2012; 11: 1475–88. raphy for proteome research. Anal Bioanal
combination of TiO2, SIMAC, and HILIC. J 56. Picotti P, Aebersold R. Selected reaction Chem. 2011; 399: 229–41.
Proteomics. 2012; 75: 5749–61. monitoring-based proteomics: workflows, 70. Bingley PJ, Williams AJ. Validation of
42. Kweon HK, H akansson K. Selective zirco- potential, pitfalls and future directions. Nat autoantibody assays in type 1 diabetes:
nium dioxide-based enrichment of phos- Methods. 2012; 9: 555–66. workshop programme. Autoimmunity.
phorylated peptides for mass 57. Wang Q, Chaerkady R, Wu J, et al. Mutant 2004; 37: 257–60.
spectrometric analysis. Anal Chem. 2006; proteins as cancer-specific biomarkers. Proc 71. Zangar RC, Daly DS, White AM. ELISA
78: 1743–9. Natl Acad Sci U S A. 2011; 108: 2444–9. microarray technology as a high-through-
43. N€uhse TS, Stensballe A, Jensen ON, et al. 58. Unwin RD, Griffiths JR, Leverentz MK, put system for cancer biomarker validation.
Large-scale analysis of in vivo phosphory- et al. Multiple reaction monitoring to iden- Expert Rev Proteomics. 2006; 3: 37–44.
lated membrane proteins by immobilized tify sites of protein phosphorylation with 72. Caron M, Choquet-Kastylevsky G, Joubert-
metal ion affinity chromatography and high sensitivity. Mol Cell Proteomics. 2005; Caron R. Cancer immunomics using auto-
mass spectrometry. Mol Cell Proteomics. 4: 1134–44. antibody signatures for biomarker discov-
2003; 2: 1234–43. 59. Ashman K, Villar EL. Phosphoproteomics ery. Mol Cell Proteomics. 2007; 6: 1115–
44. Gruhler A, Olsen JV, Mohammed S, et al. and cancer research. Clin Transl Oncol. 22.
Quantitative phosphoproteomics applied to 2009; 11: 356–62. 73. Rai AJ, Gelfand CA, Haywood BC, et al.
the yeast pheromone signaling pathway. 60. Matros A, Kaspar S, Witzel K, et al. HUPO Plasma Proteome Project specimen
Mol Cell Proteomics. 2005; 4: 310–27. Recent progress in liquid chromatography- collection and handling: towards the stan-
45. Li X, Gerber SA, Rudner AD, et al. Large- based separation and label-free quantitative dardization of parameters for plasma prote-
scale phosphorylation analysis of alpha- plant proteomics. Phytochemistry. 2011; ome samples. Proteomics. 2005; 5: 3262–
factor-arrested Saccharomyces cerevisiae. 72: 963–74. 77.
J Proteome Res. 2007; 6: 1190–7. 61. Nahnsen S, Bielow C, Reinert K, et al. 74. Rai AJ, Vitzthum F. Effects of preanalytical
46. Albuquerque CP, Smolka MB, Payne SH, Tools for label-free peptide quantification. variables on peptide and protein measure-
et al. A multidimensional chromatography Mol Cell Proteomics. 2013; 12: 549–56. ments in human serum and plasma: impli-
technology for in-depth phosphoproteome 62. Bantscheff M, Schirle M, Sweetman G, cations for clinical proteomics. Expert Rev
analysis. Mol Cell Proteomics. 2008; 7: et al. Quantitative mass spectrometry in Proteomics. 2006; 3: 409–26.
1389–96. proteomics: a critical review. Anal Bioanal 75. Walther TC, Mann M. Mass spectrometry-
47. Luo R, Zhao H. Protein quantitation using Chem. 2007; 389: 1017–31. based proteomics in cell biology. J Cell
iTRAQ: review on the sources of variations 63. Asara JM, Christofk HR, Freimark LM, Biol. 2010; 190: 491–500.
and analysis of nonrandom missingness. et al. A label-free quantification method by 76. Budde P, Schulte I, Appel A, et al. Pepti-
Stat Interface. 2012; 5: 99–107. MS/MS TIC compared to SILAC and spec- domics biomarker discovery in mouse